Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00367770 · ClinicalTrials.gov registry record · Phase 4
BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
A Phase 4 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT00367770 is a Phase 4 study that has completed, run by Actelion. The registered enrollment target is 37 participants.
The verdict
NCT00367770, a Phase 4 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
This 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5 study (PAH related to Eisenmenger physiology). Treatment duration is 6 months.
Interventions
- DRUG Tracleer®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00367770
The ClinicalTrials.gov registry entry for NCT00367770 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tracleer® is the first listed.
NCT00367770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00367770 about?
NCT00367770 is a clinical study titled "BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology". This 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5 study (PAH related to Eisenmenger physiology). Treatment duration is 6 months.
What is the current status of trial NCT00367770?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2004-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00367770?
The interventions under investigation include: Tracleer® (DRUG).
Who is sponsoring clinical trial NCT00367770?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.